FEATURED COMPANIES
- Abbott Laboratories
- Allergan, plc
- C.R. Bard, Inc.
- Medtronic
- Mylan N.V.
- Novartis AG
The global drug device combination products market size is expected to reach USD 251.9 billion by 2030. It is expected to expand at a CAGR of 8.8% from 2022 to 2030. The rising demand for minimally invasive techniques due to enhanced patient outcomes associated with it is the high impact-rendering driver of this market. These devices facilitate early diagnosis and reduced treatment duration in a majority of surgical procedures. Growing demand is also a consequence of minimal pain, heightened cost efficiency, improved safety, better efficacy, rapid recovery, and reduced hospital stay rendered by these devices.
The increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to building a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in the future and boost overall growth during the forecast period.
Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce the need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in the case of drug-device combination products.
This product will be delivered within 1-3 business days.
The increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to building a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in the future and boost overall growth during the forecast period.
Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce the need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in the case of drug-device combination products.
Drug Device Combination Products Market Report Highlights
- by product, transdermal patches held the dominant share in 2021 owing to the increasing demand for self-administration of drugs in diseases requiring long-term treatment.
- The inhalers product segment is anticipated to exhibit a lucrative CAGR of 10.3% over the forecast period owing to the rising prevalence of chronic diseases.
- North America held the largest revenue share of over 40.0% in 2021 owing to the extensive new product development activities conducted by prominent players across this region.
- Asia Pacific is anticipated to grow at a lucrative rate over the coming years owing to the increasing healthcare spending and rising awareness levels of physicians pertaining to the benefits of these products.
- Key market players are engaged in various strategies such as new product launches and distribution agreements to gain market penetration. For instance, in February 2016, Medtronic introduced the New Resolute Onyx drug-eluting stent, commercially available in different sizes in Europe, thereby enhancing the company’s current product offerings.
- High operational cost, stringent regulatory framework, and capital requirements keep entry barriers at a higher level, owing to which, the threat of new entrants is expected to be low .
This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Drug Device Combination Products Market
What is the estimated value of the Global Drug Device Combination Products Market?
What is the growth rate of the Global Drug Device Combination Products Market?
What is the forecasted size of the Global Drug Device Combination Products Market?
Who are the key companies in the Global Drug Device Combination Products Market?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Abbott Laboratories
- Allergan, plc
- C.R. Bard, Inc.
- Medtronic
- Mylan N.V.
- Novartis AG
Chapter 1 Methodology and Scope
Chapter 4 Market Variables, Trends & Scope
Chapter 5 Market Categorization 1: Product Estimates & Trend Analysis
Chapter 6 Market Categorization 4: Regional Estimates & Trend Analysis, by Product, Application & Test
Chapter 7 Competitive Landscape
Note: Product cover images may vary from those shown
- Abbott Laboratories
- Terumo Corporation
- Stryker Corporation
- Mylan N.V.
- Medtronic
- St. Jude Medical, Inc.
- Allergan, plc
- Boston Scientific Corporation
- Novartis AG
- Teleflex Incorporated
- C.R. Bard, Inc.
- W.L.Core & Associates, Inc.
Note: Product cover images may vary from those shown
LOADING...
